Unknown

Dataset Information

Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.


ABSTRACT:

Background

Few data are available about the durability of the response, the induction of neutralizing antibodies, and the cellular response upon the third dose of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in hemato-oncological patients.

Objective

To investigate the antibody and cellular response to the BNT162b2 vaccine in patients with hematological malignancy.

Methods

We measured SARS-CoV-2 anti-spike antibodies, anti-Omicron neutralizing antibodies, and T-cell responses 1 month after the third dose of vaccine in 93 fragile patients with hematological malignancy (FHM), 51 fragile not oncological subjects (FNO) aged 80-92, and 47 employees of the hospital (healthcare workers, (HW), aged 23-66 years. Blood samples were collect

SUBMITTER: Laquintana V 

PROVIDER: S-EPMC10853639 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature